SUPN Stock Up 27% after 7-Day Win Streak
Supernus Pharmaceuticals (SUPN) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 27% return. The company has gained about $643 Mil in value over the last 7 days, with its current market capitalization at about $2.4 Bil. The stock remains 17.4% above its value at the end of 2024. This compares with year-to-date returns of 7.9% for the S&P 500.
SUPN develops and commercializes treatments for central nervous system diseases in the U.S., including extended-release topiramate for epilepsy and migraine, distributing through wholesalers and specialty pharmacies. After this rally, is SUPN still a buy – or is it time to lock in gains? Deep dive with Buy or Sell SUPN.
Comparing SUPN Stock Returns With The S&P 500
The following table summarizes the return for SUPN stock vs. the S&P 500 index over different periods, including the current streak:
- Can Rivian’s Services Business 2x The Stock?
- How Broadcom Became The Most Indispensable Name In Tech
- The Nvidia Threat Masked Inside Cisco’s Results
- Catalysts That Could Propel Advanced Micro Devices Stock to the Moon
- 3 Forces That Could Shake Tesla Stock
- Could FactSet Research Systems Stock’s Cash Flow Spark the Next Rally?
| Return Period | SUPN | S&P 500 |
|---|---|---|
| 1D | 13.1% | 0.7% |
| 7D (Current Streak) | 27.0% | -0.7% |
| 1M (21D) | 32.3% | 1.9% |
| 3M (63D) | 30.9% | 13.2% |
| YTD 2025 | 17.4% | 7.9% |
| 2024 | 24.9% | 23.3% |
| 2023 | -18.9% | 24.2% |
| 2022 | 22.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has SUPN behaved after prior drops? See SUPN Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 86 S&P constituents with 3 days or more of consecutive gains and 15 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 65 | 7 |
| 4D | 17 | 2 |
| 5D | 4 | 1 |
| 6D | 0 | 4 |
| 7D or more | 0 | 1 |
| Total >=3 D | 86 | 15 |
Key Financials for Supernus Pharmaceuticals (SUPN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $607.5 Mil | $661.8 Mil |
| Operating Income | $13.4 Mil | $75.6 Mil |
| Net Income | $1.3 Mil | $73.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $149.8 Mil | $165.5 Mil |
| Operating Income | $-2.6 Mil | $12.1 Mil |
| Net Income | $-11.8 Mil | $22.5 Mil |
While SUPN stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.